Cite
HARVARD Citation
Damodaran, S. et al. (2022). Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of clinical oncology. 40 (14), pp. 1552-1561. [Online].